Awan, Farrukh

Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia

Maddocks, K. J., Ruppert, A. S., Lozanski, G., Heerema, N. A., Zhao, W., Abruzzo, L., Lozanski, A., Davis, M., Gordon, A., Smith, L. L., et al. (2015) · JAMA Oncology

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 584

BTK C481S -Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia

Woyach, J. A., Ruppert, A. S., Guinn, D., Lehman, A., Blachly, J. S., Lozanski, A., Heerema, N. A., Zhao, W., Coleman, J., Jones, D., et al. (2017) · Journal of Clinical Oncology

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 484

EPCORE NHL-1 follicular lymphoma (FL) cycle (C) 1 optimization (OPT) cohort: expanding the clinical utility of epcoritamab in relapsed or refractory (R/R) FL

Vose, J., Vitolo, U., Lugtenburg, P., Chamuleau, M. E. D., Linton, K. M., Thieblemont, C., Sonnevi, K., Jurczak, W., Olszewski, A. J., Awan, F. T., et al. (2024) · Journal of Clinical Oncology

Lymphoma Diagnosis and TreatmentCAR-T cell therapy research

Cited by 10